Seelos Therapeutics (NASDAQ: SEEL) stock dropped 69% yesterday and a further 9% today. That’s 80% off SEEL stock in the one, slightly protracted, move. The reason why is the failure of the Phase II test. What might be worse is the reason for the failure. The observed results weren’t that bad if we’re to be honest about it. But there weren’t enough participants to achieve statistical relevance. And that’s bad, because that’s something that is under the control of the management.
The announcement: “Seelos Therapeutics, Inc. (SEEL) reported top line data showing clinically meaningful treatment effects across multiple endpoints and a well-tolerated safety profile from the double-blind, placebo-controlled cohort of its Phase II study of SLS-002 for Acute Suicidal Ideation and Behavior in adults with Major Depressive Disorder. The company said target enrollment of the study was 220 patients, however, due to financial constraints, only 147 patients were randomized. Due to the limited sample size, the study did not meet the pre-defined primary endpoint.”

Seelos Therapeutics stock price from Google Finance
It’s possible to ask - indeed should be asked - why Seelos went ahead with the testing - an expensive process - without enough participants in the trial.
The results themselves, as they say, were encouraging. Which should be fairly obvious, they’re testing a form of ketamine on depression. Which we already know, from large numbers of people taking it illegally, has some effects. Which, in fact, makes this testing result worse. Because we already knew the effect was there. All that was necessary was to do the tests well enough to prove it to medical standards. Which is what wasn’t done. Tsk.
A likely knock on effect of this is to the other companies testing psychedelics for medical uses. There has been, just these past few weeks, liberalisation of the rules about who can test what. But someone running a test like this is unlikely to give stock prices across the sector another boost.
The truth here is that Seelos just didn't run that test well.



